Valneva: quarterly results boosted by PRV sale
The vaccines company saw total sales fall by 2% to 32.8 million euros, with product sales stable at 32.1 million, including 16.6 million for Ixiaro/Jespect (Japanese encephalitis) and 11.3 million for Dukoral (cholera).
Valneva confirms that it expects total sales for the current year to be between 170 and 190 million euros, including 160 to 180 million thanks to growth in sales of its proprietary vaccines.
"For the remainder of the year, we expect to continue to benefit from the recovery in the travel industry, and at the same time achieve the various R&D milestones we have set ourselves", says CFO Peter Bühler.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction